Characterizing and classifying neuroendocrine neoplasms through microRNA sequencing and data mining

Jina Nanayakkara1, Kathrin Tyryshkin1, Xiaojing Yang1

  • 1Laboratory of Translational RNA Biology, Department of Pathology and Molecular Medicine, Queen's University, 88 Stuart Street, Kingston, ON K7L 3N6, Canada.

NAR Cancer
|August 4, 2020
PubMed

Insights

MicroRNAs (miRNAs) can classify neuroendocrine neoplasms (NENs). This study identified specific miRNA markers and developed a machine learning classifier, achieving 98% accuracy in distinguishing NEN types and aiding diagnosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Neuroendocrine neoplasms (NENs) present clinical diversity and classification challenges.
  • MicroRNAs (miRNAs) show potential as molecular markers for cancer classification.
  • Integrating molecular data into NEN classification frameworks is crucial.

Purpose of the Study:

  • To investigate the utility of miRNA expression profiling for NEN classification.
  • To identify common and type-specific miRNA markers across diverse NENs.
  • To develop a machine learning-based miRNA classifier for NENs.

Main Methods:

  • Compiled and analyzed 378 miRNA expression profiles from 221 NEN and 114 non-NEN samples.
  • Utilized unsupervised hierarchical clustering and comparative analyses to identify differential miRNA expression.
  • Applied machine learning algorithms to construct a miRNA-based diagnostic classifier.

Main Results:

  • Hierarchical clustering effectively distinguished NENs from non-NENs.
  • miR-375 and miR-7 were significantly upregulated in NENs compared to controls.
  • A 17-miRNA signature achieved 98% accuracy in classifying 15 NEN pathological types, correcting one histological diagnosis.

Conclusions:

  • Convergent miRNA expression programs exist across NENs from different anatomical sites.
  • Identified robust miRNA biomarkers for NEN classification and subtyping.
  • Developed an accurate miRNA-based classifier, enhancing NEN diagnosis and understanding of tumor diversity.